close

Enter

Log in using OpenID

Thyroid Cancer Drugs Market

embed
In the recent past, increasing number of thyroid cancers were diagnosed at an early stage of the treatment as several new technologies has arrived with drugs.
Thyroid Cancer Drugs Market - Global Industry
Insights, Trends, Outlook, and Opportunity Analysis,
2018-2026
In the recent past, increasing number of thyroid cancers were diagnosed at an early stage of
the treatment as several new technologies has arrived with drugs. Advanced treatments resulting
into long term survival, minimum complications of surgery and improved quality of life in a
cost-effective way. The main types of thyroid cancer includes differentiated, medullary, and
anaplastic thyroid cancer. Among these, anaplastic thyroid cancer is characterized with an
aggressive undifferentiated tumor. Apart from these, the other types of thyroid cancer includes
thyroid lymphomas, thyroid sarcomas, parathyroid cancer or other rare thyroid tumors.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1710
Thyroid Cancer Drugs Market Drivers
Increasing prevalence of thyroid cancer is expected to drive growth of the thyroid cancer drugs
market. For instance, according to National Cancer Institute (NCI), 2013-2015 data findings,
around1.2% of men and women are expected to be diagnosed with thyroid cancer at some
point during their lifetime, in the U.S. Moreover, according to the NCI 2018 data findings, in
2018, there were an estimated 53,990 new cases of thyroid cancer and an estimated 2,060
people are expected to die due to thyroid cancer, in the U.S. Moreover, according to Cancer
Research UK, 2015 data findings, in the U.K. there were 3,528 new cases of thyroid cancer
registered in 2015. According to the same source, thyroid cancer accounted to register 1% of all
cancer cases in 2015, which includes 27% of thyroid cancer cases in males, and 73% in
females, in the U.K. Furthermore, according to Cancer Research UK, the lifetime risk of
developing thyroid cancer is around 1 in 480 for men and around 1 in 180 for women, in 2012
in the U.K.
In 2016, according to the American Cancer Society, anaplastic thyroid cancer accounts for 2%
of all thyroid cancers, in North America. FDA granted several programs, in order to increase
availability of drugs to treat serious diseases. In May 2018, Food and Drug Administration
(FDA) approved a combination of two targeted drugs, dabrafenib plus trametinib, to treat
patients with anaplastic thyroid cancer. The combination of Tafinlar (dabrafenib) and Mekinist
(trametinib) is the first FDA approved treatment for these type of thyroid cancers. Moreover, in
2015, FDA approved Lenvatinib for the treatment of locally recurrent or metastatic, progressive,
radioactive iodine-refractory differentiated thyroid cancer. In November 2013, U.S. FDA
approved Nexavar (sorafenib) to treat patients with Stage IV thyroid cancer. Moreover, the drug
is already present in the market for the treatment of liver and kidney cancer.
Report includes chapters which deeply display the following deliverable about industry :
• Thyroid Cancer Drugs Market Research Objective and Assumption
• Thyroid Cancer Drugs Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Thyroid Cancer Drugs Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Thyroid Cancer Drugs Market , By Regions
• Thyroid Cancer Drugs Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Thyroid Cancer Drugs Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Thyroid Cancer Drugs Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Thyroid Cancer Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Thyroid Cancer Drugs Market - Regional Analysis
Geographically, thyroid cancer drugs market is segmented into North America, Latin America,
Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in
thyroid cancer drugs market. This is owing to growing prevalence of thyroid cancer in this
region. According to National Cancer Institute (NCI) 2018 data findings, in 2015, there were an
estimated 765,547 people living with thyroid cancer in the U.S. Moreover, according to the
same source, an estimated 53,990 new cases of thyroid cancer are expected to be registered in
2018, representing 3.1% of all new cancer cases, in 2018.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1710
Thyroid Cancer Drugs Market Competitive Landscape
Some of the key players operating in thyroid cancer drugs market include Biovista, Vascular
Biogenics, Azaya Therapeutics, Bionomics, Bayer, Eisai, Bio-Path Holdings, Takeda
Pharmaceutical Company, GlaxoSmithKline plc, and AstraZeneca plc. Key players in the market
are focusing on organic growth strategies, in order to enhance its market share and retain its
position in the market. For instance, in May 2016, U.S. Food and Drug Administration (FDA)
granted Orphan Drug Designation for AstraZeneca’s investigational MEK 1/2 inhibitor,
selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer
(DTC). Moreover, in April 2011, FDA approved AstraZeneca’s kinase inhibitor vandetanib for the
treatment of unresectable or metastatic medullary thyroid cancer.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge339   documents Email
Document
Category
Health and Medicine
Views
7
File Size
110 KB
Tags
thyroid, Thyroid Cancer Drugs Market
1/--pages
Report inappropriate content